NKGen Biotech, Inc.: auditor change — Graf Acquisition Corp. IV restates Q2 and Q3 2022 financials; material weakness in internal controls

NKGen Biotech, Inc.

Non-reliance on previously issued unaudited interim financials for Q2 and Q3 2022 due to accounting error on deferred underwriting fee waiver.
Error: waiver of deferred underwriting fee should have been credited to stockholder's deficit, not recognized as extinguishment gain in operations.
Material weakness in internal control over financial reporting identified as of December 31, 2022.
Restatement expected in annual report on Form 10-K for year ended December 31, 2022; no impact on cash or trust account.

item 4.02

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

NKGen Biotech, Inc. reported that prior financial statements should not be relied upon.

Action: non reliance

Exact text from the filing

On March 28, 2023, the Company’s management and the audit committee of the Company’s board of directors (the “Audit Committee”) concluded that the Company’s previously issued unaudited interim financial statements included in the 10-Qs should no longer be relied upon and that it is appropriate to restate the 10-Qs.

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0001104659-23-040171

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.